A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

October 7, 2021

Study Completion Date

October 7, 2021

Conditions
Advanced Solid TumorB Cell Lymphoma
Interventions
DRUG

CN1

Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.

Trial Locations (1)

4101

Mater Medical Centre, Brisbane

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Curon Biopharmaceutical (Australia) Co Pty Ltd

INDUSTRY

NCT04418141 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 | Biotech Hunter | Biotech Hunter